Log in

Clinigen Group Share Forecast, Price & News

GBX 602
-1.50 (-0.25 %)
(As of 10/30/2020 05:35 PM ET)
Today's Range
Now: GBX 602
50-Day Range
MA: GBX 638.54
52-Week Range
Now: GBX 602
Volume178,852 shs
Average Volume455,278 shs
Market Capitalization£800.83 million
P/E Ratio59.02
Dividend Yield1.34%
Clinigen Group plc operates as a specialty pharmaceutical and services company. The company operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Trial Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines in the Africa and Asia Pacific region. The Unlicensed Medicines segment is involved in sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Clinical Trial Segment supplies and manages comparator medicines and services to clinical trials and investigator initiated trials. It offers Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Foscavir, an anti-virals which work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company has a strategic alliance with Cumberland Pharmaceuticals Inc. Clinigen Group plc was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.
Read More
Clinigen Group logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.03 out of 5 stars

Industry, Sector and Symbol

Industry Drug Delivery



Sales & Book Value

Annual Sales£504.30 million
Cash FlowGBX 107.09 per share
Book ValueGBX 335.50 per share



Market Cap£800.83 million
Next Earnings DateN/A
OptionableNot Optionable
GBX 602
-1.50 (-0.25 %)
(As of 10/30/2020 05:35 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CLIN News and Ratings via Email

Sign-up to receive the latest news and ratings for CLIN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Clinigen Group (LON:CLIN) Frequently Asked Questions

How has Clinigen Group's stock been impacted by COVID-19 (Coronavirus)?

Clinigen Group's stock was trading at GBX 657 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CLIN shares have decreased by 8.4% and is now trading at GBX 602.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Clinigen Group?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clinigen Group in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Clinigen Group

How were Clinigen Group's earnings last quarter?

Clinigen Group PLC (LON:CLIN) announced its quarterly earnings data on Thursday, September, 17th. The company reported $65.60 earnings per share for the quarter, beating the Zacks' consensus estimate of $63.50 by $2.10.
View Clinigen Group's earnings history

How often does Clinigen Group pay dividends? What is the dividend yield for Clinigen Group?

Clinigen Group declared a dividend on Thursday, September 17th. Shareholders of record on Thursday, November 5th will be paid a dividend of GBX 5.46 per share on Wednesday, December 2nd. This represents a dividend yield of 0.85%. The ex-dividend date is Thursday, November 5th. This is an increase from Clinigen Group's previous dividend of GBX 2.15. The official announcement can be accessed at this link.
View Clinigen Group's dividend history

What price target have analysts set for CLIN?

4 brokers have issued 1 year target prices for Clinigen Group's stock. Their forecasts range from GBX 820 to GBX 1,300. On average, they anticipate Clinigen Group's stock price to reach GBX 997.50 in the next year. This suggests a possible upside of 65.7% from the stock's current price.
View analysts' price targets for Clinigen Group

Who are some of Clinigen Group's key competitors?

What other stocks do shareholders of Clinigen Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Clinigen Group investors own include Comerica (CMA), Honda Motor (HMC), Advanced Accelerator Applicatio (AAAP), Albemarle (ALB), First Hawaiian (FHB), Landec (LNDC), NII (NIHD), 228608 (RTI), General Electric (GE) and NetApp (NTAP).

Who are Clinigen Group's key executives?

Clinigen Group's management team includes the following people:
  • Mr. Shaun Edward Chilton, CEO & Exec. Director (Age 51)
  • Mr. Nicholas Keher, CFO & Director
  • Ms. Debra Ainge, Chief Operating Officer
  • Matt Parrish, Head of Investor Relations
  • Mr. David Bryant, Director of Corp. Devel.

What is Clinigen Group's stock symbol?

Clinigen Group trades on the London Stock Exchange (LON) under the ticker symbol "CLIN."

How do I buy shares of Clinigen Group?

Shares of CLIN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Clinigen Group's stock price today?

One share of CLIN stock can currently be purchased for approximately GBX 602.

How big of a company is Clinigen Group?

Clinigen Group has a market capitalization of £800.83 million and generates £504.30 million in revenue each year. Clinigen Group employs 849 workers across the globe.

What is Clinigen Group's official website?

The official website for Clinigen Group is www.clinigengroup.com.

How can I contact Clinigen Group?

Clinigen Group's mailing address is Pitcairn House Crown Square, First Avenue, STAFFORDSHIRE, DE14 2WW, United Kingdom. The company can be reached via phone at +44-1283-495010.

This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.